Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy
Clinical trial NCT05979220 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT05979220
- Sponsor
- Shuangyue Liu
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-01
- Primary completion
- 2024-06-30
- Enrollment
- 178
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.